rituximab

all catalysts(0)

nothing on the calendar yet

News(10)

• Caribou to stop R&D work, start ‘substantial’ job cuts
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 14h ago
• Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
  New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…
  biospace · 1d ago
• AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3
  AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse la…
  biospace · 2d ago
• ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
  When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
  fiercebiotech · 10d ago
• China’s Henlius carves out $440M T-cell engager deal with Amberstone
  Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers.
  fiercebiotech · 14d ago
• Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
  Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
  biopharma_dive · 20d ago
• Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
  The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
  biopharma_dive · 3mo ago
• An ADC specialist sinks on safety concerns for blood cancer drug
  Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
  biopharma_dive · 4mo ago
• A Spanish biotech banks $87M to make differentiated ADCs
  Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
  biopharma_dive · 4mo ago
• Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer
  Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.
  onclive · 4mo ago